Categories: News

San Antonio Based Companies NanoHarmonics and Avagen Pharma Have Joined Forces to Transform Healthcare with Nanotechnology

SAN ANTONIO, Jan. 8, 2022 /PRNewswire-PRWeb/ — NanoHarmonics, a pioneer in nanotechnology diagnostics, has partnered with Avagen Pharma, a Texas based nano-pharmaceutical company to further its mission in transforming healthcare through disruptive nanotechnology.

Avagen Pharma focuses on novel pharmaceutical products using a patented nanotechnology called NanoPro Rx™. NanoHarmonics utilizes a proprietary form of nanotechnology, Quantum Dots, called Abacus™ in their patented diagnostic platform. “Our focus is to use nanotechnology to create or improve pharmaceutical and diagnostics within healthcare. This is a great time to bring together our different nanotechnology platforms and use internal synergies between both companies to improve the efficacy, safety, and accessibility of certain healthcare products for people all over the world,” says Justin Jones, CEO of Avagen Pharma.

“Our collaboration with Avagen Pharma will allow us to truly revolutionize healthcare through practical applications of nanotechnology,” says Jimi Sta Maria, Chairman and CEO of NanoHarmonics. Both companies will be jointly headquartered in San Antonio, TX.

More information about Avagen Pharma, Inc. can be found at http://www.AvagenPharma.com or follow Avagen Pharma on facebook, instagram and twitter.

About Avagen Pharma:

Avagen Pharma, Inc. is headquartered in San Antonio, TX. It focuses on products to fill voids where current options do not exist and creates faster and less invasive ways to improve current diagnostics. Avagen uses this expertise to focus on dynamic products that will truly enhance a person’s health and well-being.

About NanoHarmonics:

NanoHarmonics’ patented Quantum Dot technology, Abacus™ is the foundation of its diagnostic platform. NanoHarmonics helps create safer, more effective, and accessible products through quantitative diagnostics, biomarker detection, therapy monitoring and rapid resulting.

Media Contact

Erin Robinson, Avagen Pharma, 1 2144158773, erin@avagenpharma.com

Twitter

 

SOURCE Avagen Pharma

Staff

Recent Posts

Methodist Le Bonheur Healthcare named among Best in Cancer Care by Money magazine

MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…

2 days ago

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…

2 days ago

KORE Helps mCare Digital Launch the Next Generation of Personal Emergency Technology

mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…

2 days ago

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…

2 days ago

Hitachi’s Holography Electron Microscope Attains Unprecedented Resolution

Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…

2 days ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…

2 days ago